| scholarly article | Q13442814 |
| P50 | author | Jorge Reis-Filho | Q23892845 |
| Robert A Soslow | Q37839435 | ||
| Salvatore Piscuoglio | Q41195760 | ||
| Britta Weigelt | Q71780641 | ||
| Caterina Marchiò | Q88051049 | ||
| P2093 | author name string | Charlotte K Y Ng | |
| Maria R De Filippo | |||
| P2860 | cites work | Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors | Q24305218 |
| Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus | Q24600932 | ||
| PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis | Q26992267 | ||
| Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. | Q27851999 | ||
| Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer | Q27852608 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal | Q28288215 | ||
| Integrated genomic characterization of endometrial carcinoma | Q28289962 | ||
| Mutational landscape and significance across 12 major cancer types | Q28300353 | ||
| Signatures of mutational processes in human cancer | Q29547191 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| PI3K pathway alterations in cancer: variations on a theme | Q29615530 | ||
| Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase | Q30156937 | ||
| A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies | Q33397006 | ||
| Theories of endometrial carcinogenesis: a multidisciplinary approach | Q33886758 | ||
| Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks | Q34077139 | ||
| Microsatellite instability and ploidy status define three categories with distinctive prognostic impact in endometrioid endometrial cancer | Q34227653 | ||
| PTEN mutations and evolving concepts in endometrial neoplasia | Q34501209 | ||
| A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas | Q34694344 | ||
| PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors | Q34769343 | ||
| AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer | Q34990362 | ||
| PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer | Q35050913 | ||
| Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group | Q35172203 | ||
| High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability | Q35275603 | ||
| The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling | Q35479152 | ||
| Rare cancer-specific mutations in PIK3CA show gain of function | Q35720258 | ||
| The management of serous papillary uterine cancer | Q36559234 | ||
| EMu: probabilistic inference of mutational processes and their localization in the cancer genome | Q36872480 | ||
| PI3K pathway dependencies in endometrioid endometrial cancer cell lines | Q36980561 | ||
| Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer | Q38042638 | ||
| Classification of endometrial carcinoma: more than two types | Q38215703 | ||
| High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma | Q40345165 | ||
| Mutant PIK3CA promotes cell growth and invasion of human cancer cells | Q40410776 | ||
| Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen | Q44850155 | ||
| Detection of microsatellite instability in endometrial cancer: advantages of a panel of five mononucleotide repeats over the National Cancer Institute panel of markers. | Q54616917 | ||
| The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways | Q73459314 | ||
| PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters | Q80209882 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 321-328 | |
| P577 | publication date | 2015-02-18 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas | |
| P478 | volume | 137 |
| Q37466261 | Analysis of in vitro chemoresponse assays in endometrioid endometrial adenocarcinoma: an observational ancillary analysis |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q47240157 | Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing |
| Q64274212 | Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors |
| Q51032285 | Next-Generation Sequencing. |
| Q90654533 | Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer |
| Q38820391 | The future therapy of endometrial cancer: microRNA's functionality, capability, and putative clinical application. |
Search more.